Test Price
2,800 AED✅ Home Collection Available
CAV3 Gene Distal Myopathy (Tateyama Type) Genetic Test in UAE – 2,800 AED
Executive Summary & Core Metrics
Accuracy Guarantee
99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing (Cert: INT/EGQ/2509DA/3139).
Premium Logistics
VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
Clinical Guidance
Telephonic Post-Test Clinical Guidance in result interpretation by a DHA-licensed specialist.
Insurance & Billing
Direct Billing Verification via WhatsApp at +971 54 548 8731. We handle all major UAE insurers.
Test Overview & Methodology
This advanced Next‑Generation Sequencing (NGS) test analyzes the entire coding region of the CAV3 gene to detect pathogenic variants linked to distal myopathy, Tateyama type—a rare, dominantly inherited muscle disorder causing progressive weakness beginning in the hands and feet. The test requires a DNA sample from blood, extracted DNA, or a single drop on an FTA card. Results are delivered in 3 to 4 weeks with a comprehensive clinical interpretation. A mandatory pre‑test genetic counselling session is included to draw your family pedigree and guide you through the implications.
| Feature | Our Test: NGS CAV3 Full Gene Analysis | Alternative: Sanger Single‑Exon Sequencing |
|---|---|---|
| Precision & Coverage | Whole gene, deep coverage (≥100x) – detects known & novel variants | Limited to one or few exons; may miss deep intronic or novel mutations |
| Methodology | Illumina® NovaSeq™ with bioinformatic variant calling & ACMG classification | Capillary electrophoresis; manual analysis |
| Turnaround Time | 3–4 weeks | 4–6 weeks |
| Diagnostic Sensitivity | 99.9% (complete ORF analysis) | ~85% (mutation‑specific) |
| Cost (AED) | 2,800 | 1,800–2,200 |
Physician Insight & Safety Protocols
“Every genetic result carries profound implications for patients and their families. Our team combines advanced NGS technology with compassionate genetic counselling to ensure you fully understand your report and its clinical correlation. Although this test identifies pathogenic CAV3 variants with high accuracy, the final diagnosis must be made by a specialist neurologist, integrating physical examination, electromyography, and family history.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory: Medication Warning
Do not discontinue prescribed medication without consulting your doctor. Genetic test preparation does not require any change to your current treatment plan.
Exclusion Criteria & Emergency Red Flags
- Individuals under 18 years without legal guardian consent (per UAE Child Data Safety regulations).
- Acute febrile illness or recent trauma that may affect sample quality – reschedule after recovery.
- Pregnant women require additional pre‑test genetic counselling and informed consent.
- Red Flags: If you develop sudden, severe muscle weakness, difficulty breathing, or chest pain, call 998 immediately and inform the emergency physician about this pending genetic test.
Patient FAQ & Clinical Guidance
1. What is the CAV3 gene distal myopathy Tateyama type NGS test?
The CAV3 NGS test identifies pathogenic variants in the caveolin‑3 gene causing distal myopathy, Tateyama type, with >99.9% accuracy. The test screens the entire coding region of the CAV3 gene using Next‑Generation Sequencing. It confirms the genetic diagnosis and differentiates Tateyama‑type distal myopathy from other muscle diseases with similar clinical presentation.
2. Why is this test necessary if I have symptoms of muscle weakness?
This test helps neurologists confirm the genetic cause of progressive distal limb weakness, enabling personalized management and family planning. A positive result can avoid unnecessary muscle biopsies, guide treatment decisions, and inform family members about their own risk. It is particularly important if you have a family history of similar symptoms or are considering reproductive options.
3. What preparation is needed before giving my sample?
Provide a detailed clinical history and undergo a pre‑test genetic counselling session to draw a family pedigree chart. There are no dietary or medication restrictions. The genetic counsellor will explain the test scope, potential outcomes, and implications. A small blood sample (or buccal swab) is collected at our DHA‑accredited laboratory or during a VIP home visit.
UAE Regulatory & Data Privacy Adherence
Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields govern the handling of your genetic data. All results are stored on encrypted servers and shared only with your consent. Federal Decree-Law No. 4 of 2016 on Medical Liability ensures patient safety and informed consent throughout the testing process. DNA Labs UAE is fully compliant with these regulations.
Clinical & Logistical Metadata
| Test Name | CAV3 Gene Distal Myopathy (Tateyama Type) Full Gene Sequencing |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Peripheral whole blood (EDTA) or extracted DNA or FTA card |
| Methodology Used | Next-Generation Sequencing (NGS) – Illumina NovaSeq |
| ICD-10-CM Code | G71.0 |
| LOINC Code | 21636-6 |
| DHA Facility License & Address | License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians